|
Complete preoperative chemotherapy regimen FLOT: Evaluating the safety and histopathologic results in gastric cancer (GC). |
|
|
Research Funding - Merck Sharp & Dohme |
Travel, Accommodations, Expenses - Merck Serono |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Lilly; Merck Serono; Novartis; Roche/Genentech |
Speakers' Bureau - Lilly; Novartis; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; MSD |
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Lilly; MSD |
Research Funding - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Medivation; Merck Sharp & Dohme; Roche |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb |
Other Relationship - Boehringer Ingelheim |